Brief: Sienna Biopharmaceuticals To Explore Financial, Strategic Alternatives
05/08/2019 17:18
Aug 5 (Reuters) - Sienna Biopharmaceuticals Inc SNNA.O :
* SIENNA BIOPHARMACEUTICALS ENGAGES COWEN TO EXPLORE FINANCIAL AND STRATEGIC
ALTERNATIVES
* SIENNA BIOPHARMACEUTICALS INC - DOES NOT INTEND TO INITIATE ITS PLANNED
PHASE 3
TRIALS OF SNA-120 UNTIL COMPANY SECURES SUFFICIENT ADDITIONAL CAPITAL
* SIENNA BIOPHARMACEUTICALS - WILL CONTINUE TO EXPLORE CAPITAL RAISING TO
ENABLE
INITIATION OF ITS PLANNED PHASE 3 PIVOTAL CLINICAL TRIALS FOR SNA-120
Source text for Eikon: ID:nGNX70J3rH
Further company coverage: SNNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sienna Biopharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Adobe, Oracle, Snap, Phreesia, Sarepta, Aquestive Therapeutics, Patterson-UTI
U.S. STOCKS ON THE MOVE-Lululemon, GE, Starbucks, Delta Air Lines, Lumber Liquidators, Lovesac
Sienna Biopharma: Falls on Nasdaq delisting plans
Brief: Sienna Biopharma Says Bankruptcy Court Approved Sale Of Assets Related To SNA-001 For $1.7 Mln In Cash
Brief: Sienna Biopharmaceuticals Announces Court Approval Of Chapter 11 Bidding Procedures